News Archive

President Donald Trump’s bold executive order on drug pricing isn’t just policy—it’s a revolution in healthcare affordability. The plan is simple yet transformative: ensure Americans pay no more for medications

Stepping onto the scale is about as American as eating apple pie, watching baseball, and visiting the drive-thru at McDonald’s.  Since U.S. adult obesity rates have doubled since 1990 (from

GLP-1 receptor agonists (GLP-1 RAs), medications that help control type 2 diabetes and obesity, can have a profound impact on physical wellness – but what about mental health? Some examples

Our country is obsessed with weight loss. From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get lean. But

FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past few years. Part of that controversy deals with the side effects

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight loss drugs.  The Ozempic maker’s chief

The protein-in-everything trend has flared up at times over the past decade, but current conditions — with tailwinds from health and wellness now supercharged by the arrival of Ozempic and

A growing number of users say Ozempic is rewiring their taste buds in ways they never saw coming. The blockbuster weight loss drug isn’t just shrinking waistlines. It’s changing how

The struggle to obtain these medications illustrates the dangerous mess the US healthcare system has become, writes the former FDA chief The American healthcare system is broken. It is too

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for type 2 diabetes (T2DM), obesity, and cardiovascular disease.1–3 Beyond these indications, they have shown promising clinical efficacy in conditions such

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.

Patients taking a GLP-1 for diabetes have a lower risk for AF at 3 years than those on other medications, report investigators who say weight loss does not fully explain

Most people would agree they could shed a few pounds. Not everyone, however, is prepared to stick to a diet or put in the time at the gym. They’d rather

Post Content

A Wegovy weight loss pill from Novo Nordisk is forthcoming, providing an alternative to injectable GLP-1 drugs. Mads Claus Rasmussen/Ritzau Scanpix/AFP via Getty Images Federal regulators have accepted Novo Nordisk’s

(MedPage Today) — GLP-1 receptor agonists for patients with diabetes was not associated with an increased risk for acute pancreatitis, a multicenter analysis found. (American Journal of Gastroenterology) Allogeneic hematopoietic

THURSDAY, May 15, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may cut the risk of obesity-related cancer (ORC) in patients being treated for diabetes and obesity, according to a

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s

Physical activity is essential for body weight maintenance after body weight-loss, partly by promoting the coupling between energy intake and expenditure. However, the underlying mechanisms remain largely unknown. Here we

Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still prefer to lose weight without using medications. For those preferring a

Learn about SYNT-101, the emerging treatment for obesity that combines the best of two proven methods.

Industry stakeholders can take steps to better understand the needs and preferences of GLP-1 patients who seek to address one—and often multiple—aesthetic concerns.

A new study has found GLP-1s may reduce the risk of developing obesity-related cancers by 41% compared to bariatric surgery — a benefit researchers believe could be tied to the

For the same pharmaceutical products, US prices can be anywhere between two and ten times higher in US markets compared to prices across the border. Nor is importation allowed, even

The Vitamin Shoppe stocks 6,000 items. GLP-1 complements are the latest to join them.

Peptidomimetics, synthetically modified peptides which have been engineered to eliminate certain undesirable features of native therapeutic peptides including short half-lives, immunogenicity, and delivery challenges, are a growing class of peptide-based

A recent study presented at the European Congress on Obesity reveals that individuals using weight loss drugs, including newer GLP-1 medications, tend to regain all lost weight within a year

The cost of prescription drugs in the U.S. has long outpaced that of peer nations, a dynamic driven by a combination of regulatory gaps, market forces, and lobbying pressure. Now,

This systematic review and meta-analysis examines data for patients with diabetes and/or obesity from trials of GLP1-RA treatment to evaluate psychiatric, cognitive, and quality-of-life outcomes compared with placebo.

Weight-loss medications and bariatric surgery have both been found effective at helping people shed excess pounds — and now a new study explores their link to obesity-related cancer (ORC) risk.

On the heels of President Donald Trump’s Monday announcement of an executive order that will slash prescription drug prices in the U.S., the spotlight is on current costs and how

Nature Communications, Published online: 13 May 2025; doi:10.1038/s41467-025-59485-9 Myostatin and activin A are the two primary negative regulators of muscle mass. Blocking these circulating ligands during GLP-1 therapy induces improved

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and researchers have struggled to answer a deceptively simple question: Who should

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being

What You Should Know:  – Veradigm, a provider of healthcare data and technology solutions, today announced a significant advancement in the application of artificial intelligence (AI) to scale the generation

(MedPage Today) — Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial. By week 72, participants on the dual GIP/GLP-1 receptor agonist

President Donald Trump signed an executive order May 12 directing drugmakers to sell medicines in the U.S. at prices similar to those offered in other wealthy countries, or face penalties

For years, researchers had been searching for hormones that promote insulin secretion. These hormones, known as incretins, could be the key to helping treat type 2 diabetes (T2D). In the

MONDAY, May 12, 2025 — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in Diabetes, Obesity and